Background
Brian Rifkin
Potassium Rollercoaster Heartbreak

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

Potassium Rollercoaster Heartbreak
Background
Jade Teakell
FLOZINATing to the Future- Long Term Effects of ...

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Background
Brian Rifkin
The Ondansetron Ballet: Torsades de Pointes

Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?

The Ondansetron Ballet: Torsades de Pointes
Background
Cristina Adriana Popa
Re”FINE”ing the role of non steroidal MRAs in ...

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome
Background
Cristina Adriana Popa
Playing It Safe: Can Felzartamab Fill the Gap ...

This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial

Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?

Must read story about Renal Denervation in Europe

"Of course we need to reflect on and take in the key learnings from SYMPLICITY HTN-3, but why should one trial all of a sudden erase all of the other data?"

-- EuroPCR course codirector, Dr William Wijns

Wijns disclosed receiving institutional grant support from Abbott Vascular, Biosensors International, Biotronik, Boston Scientific, Cordis, Medtronic, and St Jude Medical

“It is difficult to get a man to understand something, when his salary depends on his not understanding it.”

-- Upton Sinclair

Great article by Shelley Wood tipped by John Mandrola

The First NephJC Google Hangout

We are interested in finding innovative ways to share the collective wisdom of the nephrology community. The Twitter discussions have been excellent so far. Our next experiment is a Google Hangout, which is a video chat. The idea is that we will present a new journal article on alternating Tuesdays. Then on the off Tuesday we will broadcast a Google Hangout which will summarize the previous week's Twitter Chat and introduce the next week's journal club article. This will provide a tick-tock rhythm to NephJC.

We are new to Google Hangouts so we will be experimenting with various formats. For the first one we will have one of the article's authors, Vlado Perkovic join Joel Topf, Paul Phelan and Hiremath Swapnil on the Hangout. We will take audience questions during the hangout.

Each hangout will be recorded and added to commentary on the article.


I fixed up the wikipedia article on atrasentan

The new journal club for Tuesday is a study of atrasentan for diabetic kidney disease. When I wrote introduction post I went to wikipedia and learned that atrasentan had been in trials as an antineoplastic agent. I went to the Twitter and asked if anyone was using it.

He then gave me the keys to the kingdom by showing me where to search NCI site for trials. Bingo.

I was Quickly able to find the failed phase 3 trial and updated wikipedia.

Clinical practice guideline for #NephJC?

What do people think about this? Is this appropriate for journal club or is this akin to doing a review article?